Syncom Formulation (India)'s gross profit for the
three
months ended in Mar. 2024 was ₹319 Mil. Syncom Formulation (India)'s gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was ₹1,065 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Syncom Formulation (India)'s Gross Profit
For the Drug Manufacturers - Specialty & Generic subindustry, Syncom Formulation (India)'s Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syncom Formulation (India)'s Gross Profit Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Syncom Formulation (India)'s Gross Profit distribution charts can be found below:
* The bar in red indicates where Syncom Formulation (India)'s Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,065 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Syncom Formulation (India) had a gross margin of 42.74% for the quarter that ended in Mar. 2024 => Durable competitive advantage
Syncom Formulation (India) Gross Profit Related Terms
Thank you for viewing the detailed overview of Syncom Formulation (India)'s Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Syncom Formulation (India) (NSE:SYNCOMF) Business Description
Syncom Formulation (India) Ltd is in the business of pharmaceuticals. The company operates through three segments including manufacturing and dealings in Pharmaceutical drugs and formulations, Trading of commodities, and Renting of property. It manufactures and markets pharmaceutical formulation products in various dosage forms like tablets, capsules, liquids orals, liquids vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and Herbals. The company's product includes generic, antiviral, antidepressant, cough suppressant, electrolyte, histamine, estrogen, and much more. It generates maximum revenue through the Pharmaceutical drugs and formulations segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NSE:SYNCOMF has been successfully added to your 